Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
(US) Daiichi Sankyo Contact for Clinical Trial Information
CONTACT
(Asia) Daiichi Sankyo Contact for Clinical Trial Information
CONTACT
Lead
Daiichi Sankyo
With
This study will evaluate the efficacy and safety of I-DXd in participants with recurrent or metastatic solid tumors. The study will be divided into 3 parts: Stage 1, Stage 2 and an optional Stage 3. Each cohort starts with Stage 1 and may continue to Stage 2 if sufficient safety and efficacy data are observed. The EC cohort may proceed to an optional Stage 3 expansion based on the totality of available data. The HCC Safety Run-In (Phase 1) will assess the safety and tolerability of I-DXd in participants with HCC.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted